# US 2022/0265741 A1 · Novel oncolytic parvoviruses with enhanced cargo capacity, stable shRNA expression cassette and novel immunogenic properties

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0265741 A1
- Document ID: US20220265741A1
- Status: Published application
- Kind: A1
- Application number: 17/670,789
- Filed: 2022-02-14
- Published: 2022-08-25
- Earliest claimed: 2021-02-12
- Assignees: Alliance of Cardiovascular Researchers
- Applicants: Alliance of Cardiovascular Researchers
- Inventors: Antonio MARCHINI; Tiina MARTTILA; Amit KULKARNI; Eckhard U. ALT
- Web page: https://patentgrep.com/patent/US20220265741A1

## CPC

- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61P 35/00: Antineoplastic agents
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 15/86: Viral vectors
- C12N 2310/111: spanning the whole gene, or a large part of it
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2330/51: Specially adapted vectors
- C12N 2750/14321: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2750/14322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14332: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2750/14342: virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C12N 2750/14343: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Novel engineered oncolytic protoparvoviruses are described to be used in cancer therapy. The engineered protoparvoviruses contain at least one deletion in the untranslated region and a silencer sequence that remains stably integrated into the viral genome during extensive virus propagation. The novel viruses can be used for the silencing of relevant cancer-related genes, providing to the virus a new anticancer mechanism of action.

## Claims

### Claim 1

An engineered parvovirus, the parvovirus having a left palindromic terminal sequence, a coding sequence, a non-coding region, and a right palindromic terminal sequence, wherein:
a) the coding sequence comprising a first sequence encoding non-structural proteins and a second sequence encoding structural capsid proteins; and
b) a first deletion is located between the first sequence and the second sequence and a second deletion is located within the untranslated region;

### Claim 2 (depends on 1)

The engineered parvovirus of claim 1 in which the parvovirus is a rodent protoparvovirus.

### Claim 3 (depends on 2)

The engineered parvovirus of claim 2, wherein the parvovirus is H-1PV or LuIII.

### Claim 4 (depends on 3)

The engineered parvovirus of claim 3, further comprising a silencer expressing sequence inserted in the non-coding region.

### Claim 5 (depends on 4)

The engineered parvovirus of claim 4, wherein the engineered parvovirus is H-1PV and comprises a first deletion at nucleotide 2022 to 2135 of the wildtype H-1PV genome and a second deletion at position 4659-4693 of the wild type H-1PV genome.

### Claim 6 (depends on 5)

The engineered parvovirus of claim 5, wherein the silencer expression sequence is a silencer expression cassette inserted at nucleotide 4659 of the wild type H-1PV genome.

### Claim 7 (depends on 6)

The engineered parvovirus of claim 6 wherein the silencer expressing sequence is a shRNA expressing cassette.

### Claim 8 (depends on 3)

The engineered parvovirus of claim 3, wherein the shRNA expressing cassette comprising a sense sequence of a target sequence, a loop, and an antisense sequence of the target sequence and a promoter regulated by a RNA polymerase II or a RNA polymerase III.

### Claim 9 (depends on 8)

The engineered parvovirus of claim 8, wherein the shRNA expressing cassette comprises a RNA-polymerase III H1 promoter

### Claim 10 (depends on 8)

The engineered parvovirus of claim 8, wherein the shRNA silences the expression of a target gene related to cancer, wherein the target gene is oncogenes, anti-apoptotic genes, a gene critical for tumor cell growth, metastasis, acquisition of drug resistance, angiogenesis or aberrant expression of an immunomodulatory gene or a gene encoding an immunomodulatory checkpoint, cytokine, growth factor, enzyme or transcription factor.

### Claim 11 (depends on 8)

The engineered parvovirus of claim 8, wherein the target sequence is a portion of TRAF3IP2 gene or PD-L1 gene.

### Claim 12 (depends on 4)

A composition for treating a cancer, comprising effective amount of the engineered virus of claim 4, and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

The composition of claim 12, wherein composition is formulated for intravascular injection, parenteral administration, intratumoral administration or intranasal administration.

### Claim 14

An engineered LuIII parvovirus having a left palindromic terminal sequence, a coding sequence, a non-coding region, and a right palindromic terminal sequence, wherein a deletion is located within the non-coding region.

### Claim 15 (depends on 14)

The engineered LuIII parvovirus of claim 14, wherein the deletion includes nucleotides 4564 to 4579 of a wild type LuIII virus.

### Claim 16 (depends on 14)

The engineered LuIII parvovirus of claim 14, further comprising a silencer expression sequence inserted in the non-coding region and remains stably integrated during extensive virus propagation.

### Claim 17 (depends on 16)

The engineered LuIII parvovirus of claim 16, wherein the silencer expression sequence is inserted at position 4575 of the wild type LuIII genome, or position 4563 of the non-coding region of the engineered LuIII parvovirus.

### Claim 18 (depends on 17)

The engineered LuIII parvovirus of claim 17, wherein the silencer expression sequence is a shRNA expression cassette comprising a sense sequence of a portion of a target gene, a loop, an antisense sequence of the portion of the target gene, and a promoter or promoter region regulated by a RNA polymerase II or a RNA polymerase III.

### Claim 19 (depends on 18)

The engineered LuIII parvovirus of claim 18, wherein the shRNA expressing cassette contains a RNA-polymerase III H1 promoter.

### Claim 20 (depends on 16)

The engineered LuIII parvovirus of claim 16, wherein the shRNA sequence silences the expression of a target gene related to cancer, wherein the target gene is oncogenes, anti-apoptotic genes, a gene critical for tumor cell growth, metastasis, acquisition of drug resistance, angiogenesis or aberrant expression of an immunomodulatory gene or a gene encoding an immunomodulatory checkpoint, cytokine, growth factor, enzyme or transcription factor.

### Claim 21 (depends on 18)

The engineered LuIII parvovirus of claim 18, wherein the target gene is TRAF3IP2 or PD-L1.

### Claim 22 (depends on 21)

A composition for treating a cancer, comprising an effective amount of the engineered LuIII parvovirus of claim 21, and a pharmaceutically acceptable carrier.

### Claim 23 (depends on 22)

The composition of claim 22, wherein the composition is formulated for intravascular injection, parenteral administration, intratumoral administration or intranasal administration.

### Claim 24 (depends on 4)

A method of treating a cancer, comprising administering to a subject an effective amount of the engineered parvoviruses of claim 4, and a pharmaceutically acceptable carrier.

### Claim 25 (depends on 24)

The method of claim 24 wherein the cancer is glioblastoma.

### Claim 26 (depends on 24)

The method of claim 24, wherein the engineered parvovirus is an engineered H-1PV, the engineered H-1PV comprising a first deletion at nucleotide 2022 to 2135 of the wildtype H-1PV genome and a second deletion at position 4659-4693 of the wild type H-1PV genome.

### Claim 27 (depends on 16)

A method of treating a cancer, comprising administering to a subject an effective amount of the engineered LuIII parvovirus of claim 16, and a pharmaceutically acceptable carrier.

### Claim 28 (depends on 27)

The method of claim 27, wherein the engineered parvovirus is administered in combination with other anticancer agents.

### Claim 29 (depends on 27)

The method of claim 27, further comprising administering to the subject a second oncolytic virus or a viral vector.

### Claim 30

The method of 29, wherein the second oncolytic virus is an engineered H-1PV parvovirus, the parvovirus having a left palindromic terminal sequence, a coding sequence, a non-coding region, and a right palindromic terminal sequence, wherein: the coding sequence comprising a first sequence encoding non-structural proteins and a second sequence encoding structural capsid proteins; and a first deletion is located between the first sequence and the second sequence and a second deletion is located within the untranslated region, wherein the engineered H-1PV parvovirus further comprising a silencer expressing sequence inserted in the non-coding region.

### Claim 31 (depends on 30)

The method of claim 30, wherein the engineered parvovirus and the engineered LuIII parvovirus and the engineered H-1PV parvovirus are administered co-sequentially or simultaneously.

### Claim 32 (depends on 30)

The method of claim 30, wherein the engineered LuIII parvovirus and the engineered H-1PV parvovirus silence the same target gene.
